SLC5A2 and hypertrophic cardiomyopathy: In contrast to our hypothesis, both treatment with either the SGLT2 inhibitor, empagliflozin, or administration of an oral KE supplement increased circulating βOHB levels in TazKD mice, but failed to ameliorate the hypertrophic cardiomyopathy characterizing these animals.